OrbiMed’s Acceleron Pharma XLRN Stock Holding History

OrbiMed’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-601,066	Closed	-$67.6M	–	167
2020 Q3	$67.6M	Buy	601,066 +473,566	+371%	+$47.1M	0.85%	35
2020 Q2	$12.1M	Sell	127,500 -130,049	-50%	-$12.5M	0.17%	91
2020 Q1	$23.1M	Buy	257,549 +150,049	+140%	+$11.7M	0.39%	61
2019 Q4	$5.7M	Buy	+107,500	New	+$4.9M	0.08%	100
2014 Q3	–	Sell	-171,800	Closed	-$5.84M	–	147
2014 Q2	$5.84M	Sell	171,800 -1,696,000	-91%	-$56.7M	0.07%	106
2014 Q1	$64.4M	Sell	1,867,800 -249,848	-12%	-$11.3M	0.79%	38
2013 Q4	$83.9M	Buy	+2,117,648	New	+$51.1M	1.23%	29

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed's XLRN Position: Q4 2020 in Review

OrbiMed sold out of Acceleron Pharma (XLRN) in Q4 2020, closing a stake of 601,066 shares — an estimated $67.6M sold.

OrbiMed first reported a position in XLRN in Q4 2013 and held it in 7 quarters. The position peaked at $83.9M in Q4 2013. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

OrbiMed reported no remaining Acceleron Pharma position as of Q4 2020 after selling out during the quarter.
OrbiMed sold 601,066 Acceleron Pharma shares in Q4 2020, an estimated $67.6M.
OrbiMed first reported a position in Acceleron Pharma in Q4 2013 and held it in 7 quarters.
OrbiMed's Acceleron Pharma position peaked at $83.9M in Q4 2013.
253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.